Por qu los tratamientos con agonistas GLP-1 tienen un costo elevado
Abstract Strong efforts have been placed on understanding the physiological roles and therapeutic potential of the proglucagon peptide hormones including glucagon, GLP-1 and GLP-2
As the presented experiments do not report absolute changes in alcohol drinking after GLP-1R agonist treatment, the effectiveness of the different agonists cannot be compared
This drug class mimics the effects of this naturally occurring hormone, boosting metabolism regulation
For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions
